News

Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported upbeat second-quarter earnings and 2025 guidance on Thursday. The company ...
Alnylam: Amvuttra Is Just Getting Started
Alnylam Pharmaceuticals, Inc. shares soar with strong Q2 results, driven by Amvuttra's stellar U.S. launch for ATTR ...
Alnylam projects $2.65B–$2.8B 2025 revenue following AMVUTTRA ATTR-CM launch momentum
Q2 2025 Management View CEO Yvonne L. Greenstreet stated, “Alnylam is firing on all cylinders, and we're swiftly establishing ourselves as a top-tier biotech company,” emphasizing the company’s focus ...
STAT1d
Alnylam raises revenue outlook as heart drug sees quick uptake
Alnylam Pharmaceuticals’ new cardiovascular drug is off to a stronger-than-expected launch. The treatment, Amvuttra, brought ...
Alnylam jumps on full year revenue guidance raise
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) rose on Wednesday after the company raised its full year revenue outlook and ...